Publicaciones en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (7)

2023

  1. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

    The Lancet, Vol. 402, Núm. 10395, pp. 41-53

  2. Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study.

    Journal of Clinical Oncology

2022

  1. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 2, pp. 161-170

  2. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC

    ESMO Open, Vol. 7, Núm. 3

2021

  1. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 4, pp. 273-284

2019

  1. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy

    Annals of Oncology, Vol. 30, Núm. 3, pp. 439-446

2016

  1. Nivolumab ± ipilimumab treatment (Tx) efficacy, safety, and biomarkers in patients (Pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): results from the CheckMate-142 study

    Annals of Oncology, Vol. 27, pp. vi158